|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.91 USD | +0.82% |
|
-1.60% | -45.38% |
| Mar. 20 | ILJIN SNT Delivers a Letter to Aurinia Pharmaceuticals | CI |
| Mar. 07 | Aurinia Pharmaceuticals Insider Sold Shares Worth $711,094, According to a Recent SEC Filing | MT |
Aurinia Pharmaceuticals Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 175.51 million compared to USD 134.03 million a year ago. Net loss was USD 78.02 million compared to USD 108.18 million a year ago.
Basic loss per share from continuing operations was USD 0.54 compared to USD 0.76 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -45.38% | 710M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
AURINIA PHARMACEUTICALS INC. 
